Similarly, biologics targeting specific allergens, such as REGN1908/1909 (targeting Fel d 1, the cat allergen) [69] and REGN5713-5714-5715 (targeting Bet v 1, the birch pollen allergen) [213], prevent IgE-mediated allergic reactions and have demonstrated promise in clinical trials, improving allergen tolerance and symptom control. The gene discussed is IGHE; the disease is allergic disease.